One of my favourite parts of the call was when PB commented on slide 11 re progress of the two clinical trials. He said that it's all good news and doesn't see a risk in those study results. And the reports are on track to be released next month.
I think this could be a significant trigger for a re-rate of the SP which is potentially underestimated now.
Ann: Half Year FY20 results Conference call, page-27
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.64 |
Change
-0.010(0.38%) |
Mkt cap ! $1.823B | |||
| Open | High | Low | Value | Volume |
| $2.62 | $2.64 | $2.58 | $2.297M | 877.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2375 | $2.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.64 | 3584 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PNV (ASX) Chart |